Total trials
468
Active
104
Phase 3
11
Total enrollment
116,434
Pipeline matrix
Showing 40 of 49 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ato-oxy | — | — | — | — | — | 1 | |
| Oxygen | — | — | — | — | — | 1 | |
| Antibiotic loaded calcium sulfate beads | — | — | — | — | — | 1 | |
| Active Comparator: narcotic regimen with TAP block | — | — | — | — | — | 1 | |
| Active Comparator: narcotic regimen with no TAP block | — | — | — | — | — | 1 | |
| non-narcotic regimen with TAP block | — | — | — | — | — | 1 | |
| non-narcotic regimen with no TAP block | — | — | — | — | — | 1 | |
| Treprostinil Injectable Product | — | — | — | — | — | 1 | |
| Riociguat Pill | — | — | — | — | — | 1 | |
| Atomoxetine and oxybutynin | — | — | — | — | — | 2 | |
| Allopregnanolone | — | — | — | — | 2 | ||
| Pedmark® STS | — | — | — | — | — | 1 | |
| Calcipotriene | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| Tarlatamab | — | — | — | — | — | 1 | |
| 4-Aminopyridine | — | — | — | — | — | 1 | |
| 1% plain lidocaine and 0.25% plain bupivacaine | — | — | — | — | — | 1 | |
| Angiotensin | — | — | — | — | — | 1 | |
| Sterile saline | — | — | — | — | — | 1 | |
| NAC | — | — | — | — | — | 1 | |
| NAC 0mg/day | — | — | — | — | — | 1 | |
| Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks | — | — | — | — | — | 1 | |
| Ropivacaine with low, non weight based Dexamethasone additive | — | — | — | — | — | 1 | |
| Tadalafil 20 MG | — | — | — | — | — | 1 | |
| Cabozantinib + Atezolizumab | — | — | — | — | — | 1 | |
| Extended Release Metformin Hydrochloride | — | — | — | — | — | 1 | |
| gemcitabine + docetaxel | — | — | — | — | — | 1 | |
| Exercise Mobilized Prophylactic DLI | — | — | — | — | — | 1 | |
| Standard Prophylactic DLI | — | — | — | — | — | 1 | |
| Exercise Mobilized Therapeutic DLI | — | — | — | — | — | 1 | |
| Standard Therapeutic DLI | — | — | — | — | — | 1 | |
| Ziprasidone | — | — | — | — | — | 1 | |
| Olanzapine | — | — | — | — | — | 1 | |
| Isoproterenol | — | — | — | — | — | 1 | |
| Bisoprolol Fumarate Tablet 10 mg | — | — | — | — | — | 1 | |
| Nadolol | — | — | — | — | — | 1 | |
| Carvedilol 50 mg | — | — | — | — | — | 1 | |
| Roflumilast 500 Mcg Oral | — | — | — | — | — | 1 | |
| GLP1-RA | — | — | — | — | — | 1 | |
| Scopolamine | — | — | — | — | — | 1 |
9 more active programs hidden
Next readouts
- 2025-09-28
- 2025-11-07
- 2025-12-25
- 2025-12-31
- 2026-02-20
- 2026-06
- 2026-06
- 2026-06-03
- 2026-11
- 2026-11-01
Top conditions
- Breast Cancer23
- Obesity12
- Cancer12
- Depression11
- Prostate Cancer9
- Sleep8
- Obstructive Sleep Apnea7
- Hypertension7
Frequently asked questions about University of Arizona
- How many clinical trials does University of Arizona have on ClinicalTrials.gov?
- University of Arizona is listed as the lead sponsor on 468 clinical trials in ClinicalTrials.gov, 104 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Arizona's trials are in Phase 3?
- 11 of University of Arizona's trials are in Phase 3, spread across 49 active drug programs.
- What therapeutic areas does University of Arizona focus on?
- University of Arizona's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Cancer, Depression, Prostate Cancer.
- When are University of Arizona's next clinical trial readouts?
- University of Arizona has 10 upcoming primary-completion readouts tracked here; the soonest is “Wellness Intervention for Smoking and HIV”, expected around 2025-09-28.